Industry News
Biotechnology Industry News
A phase 3 trial of Sanofi’s…
A phase 3 trial of Sanofi’s eczema prospect amlitelimab has hit its primary and key secondary endpoints. Yet, with the data falling short of analyst expectations, shares in the company opened down 9% in Paris.
An interim analysis reported in…
An interim analysis reported in June showed that Amgen's Zai Labs-partnered bemarituzumab made improvements in overall survival, but the final analysis tells a different story.
Gilead Sciences’ Kite Pharma has…
Gilead Sciences' Kite Pharma has cut off a collaboration with Shoreline Biosciences, ending a research collaboration on off-the-shelf cell therapies that was valued at more than $2.3 billion.
After becoming the first group to…
After becoming the first group to therapeutically edit human RNA in October 2024, Wave Life Sciences has released more data from an ongoing alpha-1 antitrypsin deficiency clinical trial—and investors appear less enthused this time around.
The FDA has outlined a new review…
The FDA has outlined a new review process for drugs and biologics designed to treat ultra-rare genetic diseases that would allow a single-arm trial, plus other supportive data, to serve as pivotal evidence.
Treeline Biosciences has surfaced…
Treeline Biosciences has surfaced from secrecy to reveal the harvesting of a $200 million series A extension and the picking of some ripe clinical programs. The extra cash brings the Massachusetts-based oncology outfit’s total funding
Valneva has reported phase 2 data…
Valneva has reported phase 2 data on the third booster dose of its Pfizer-partnered Lyme disease vaccine candidate, ticking off another task for a prospect that could reach regulatory review next year.
Novartis has returned to Argo…
Novartis has returned to Argo Biopharmaceutical with $160 million in upfront cash to explore various cardiovascular meds in the Chinese biotech’s siRNA pipeline.
After throwing down $70 million…
After throwing down $70 million upfront to partner on Black Diamond Therapeutics’ solid tumor candidate earlier this year, Servier is pulling out its checkbook to ink yet another oncology licensing deal.
Boston-based Radiance Biopharma is…
Boston-based Radiance Biopharma is doling out $15 million in cash and offering more than $1 billion in milestones for licensing rights to a bispecific antibody-drug conjugate from a Chinese drug developer.
Cytokinetics spent Labor Day…
Cytokinetics spent Labor Day weekend in Spain, sharing a big phase 3 win for its lead cardio candidate at the European Society of Cardiology Congress in Madrid. A daily pill of small molecule aficamten improved
In the next milestone in Editas’…
In the next milestone in Editas' strategic pivot, the company revealed its new lead program as a possible one-time treatment for high cholesterol.
Amgen is putting down $600 million…
Amgen is putting down $600 million to build a new R&D site in California, a move the Big Pharma says will create hundreds of U.S. jobs.
Zenas BioPharma has secured up to…
Zenas BioPharma has secured up to $300 million from Royalty Pharma in return for royalties on sales of lead autoimmune candidate obexelimab. The cash is intended to help Zenas get its star asset across the
Vertex Pharmaceuticals is offering…
Vertex Pharmaceuticals is offering Enlaza Therapeutics more than $2 billion in biobucks through a multi-target drug discovery deal aiming to create new T-cell engagers and small-format drug conjugates.
Novartis is taking another shot at…
Novartis is taking another shot at alpha-synuclein as a target for treating Parkinson’s disease via a $200 million upfront licensing deal with Arrowhead Pharmaceuticals.
Merck & Co. has completed a…
Merck & Co. has completed a hat trick of phase 3 victories for its oral PCSK9 inhibitor. Navigating into the broader hyperlipidemia population, the drugmaker stayed out of the shoals and charted a course to
Zymeworks is abandoning a T-cell…
Zymeworks is abandoning a T-cell engager after assessing the cancer drug’s benefit-risk profile in a phase 1 study.
Upstream Bio has sailed to a…
Upstream Bio has sailed to a phase 2 win in sinusitis and plans to push its candidate forward against a competitive current.
As the oral GLP-1 race…
As the oral GLP-1 race intensifies, Eli Lilly has slimmed back the number of phase 2 trials it is conducting for one of its contenders.